Although conventional biomarkers of response to immunotherapy (PD-L1, PD-1/PD-L1 interaction, tumor mutational burden (TMB), tertiary lymphoid structure (TLS), CD8+T cell infiltration, IFN-γ, and immune activation gene signature) have been reported to be associated with clinical response in patients with metastatic melanoma (Auslander et al, 2018; Cabrita et al, 2020; Gide et al, 2019; Girault et al, 2022; Newell et al, 2022; Voabil et al, 2021), none are currently integrated into the clinical management of patients. This evidence concerns the gene CD8A and neoplasm.